Drusen maculopathy: A risk factor for AMD. Can we prevent visual loss?

Acta Ophthalmologica Scandinavica

Volumn 81, Issue 5, 2003, Pages 427-429

  Algvere, Peep V ^a   Seregard, Stefan ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CAROTENOID; COPPER DERIVATIVE; CUPRIC OXIDE; LIPOFUSCIN; LYCOPENE; RETINOL; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN; ZINC; ZINC OXIDE;

ARGON LASER; CLINICAL TRIAL; DIODE LASER; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENTIATION; DRUSEN; EDITORIAL; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER COAGULATION; LUNG CANCER; NONHUMAN; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION;

HUMANS; MACULAR DEGENERATION; RETINAL DRUSEN; RISK FACTORS; VISION DISORDERS;

EID: 0142029600     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2003.00157.x     Document Type: Editorial

References (22)

1. Age-Related Eye Disease Study Research Group (2001): A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 119: 1417-1436.
2. Algvere PV & Seregard S (2002): Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand 80: 136-143.
3. Ambati J & Ambati BK (2002): Age-related eye disease study caveats. Arch Ophthalmol 120: 997-999.
4. Ambati J, Ambati BK, Yoo SH, Ianchulev S & Adamis AP (2003): Age-related macular degeneration: aetiology, pathogenesis and therapeutic strategies. Surv Ophthalmol 48: 257-293.
5. Beatty S, Koh H-H, Phil M, Henson D & Boulton M (2000): The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45: 115-134.
6. Brunk UT & Terman A (2002): Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 33: 611-619.
7. Cho E, Stampfer MJ, Seddon JM, Hung S, Spiegelman D, Rimm EB, Willet WC & Hankinson SE (2001): Prospective study of zinc intake and the risk of age-related macular degeneration. Ann Epidemiol 11: 328-336.
8. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG & Cousins SW (2003): Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3586-3592.
9. Frennesson C (2003): Prophylactic laser treatment in early age-related maculopathy. Acta Ophthalmol Scand 81: 449-454.
10. Hayes KC (1974): Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. Invest Ophthalmol Vis Sci 13: 499-510.
11. Holz FG, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Wells JA, Minassian DC, Chisholm IH & Bird AC (1994): Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 101: 1522-1528.
12. Klein R, Klein BE, Jensen SC & Meuer SM (1997): The five-year incidence and progression of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 104: 7-21.
13. Little HL, Showman JM & Brown BW (1997): A pilot, randomized, controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 104: 623-631.
14. Macular Photocoagulation Study Group (1997): Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 115: 741-747.
15. Mares-Perlman JA, Brady WE, Klein R, Klein BEK, Bowen P, Stacevizc-Sapuntzakis M & Palta M (1995): Serum antioxidants and age-related macular degeneration in a population-based, case-control study. Arch Ophthalmol 113: 1518-1523.
16. Newsome DA, Swartz M, Leone NC, Elston SC & Miller E (1988): Oral zinc in macular degeneration. Arch Ophthalmol 106: 192-198.
17. Organisciak DT, Wang HM, Li ZY & Tso MO (1985): The protective effect of ascorbate in retinal light damage of rats. Invest Ophthalmol Vis Sci 26: 1580-1588.
18. Owens SL, Guymer RH, Gross-Jendroska M & Bird AC (1999): Fluorescein angiographic abnormalities after prophylactic macular photocoagulation for high risk age-related maculopathy. Am J Ophthalmol 127: 681-687.
19. Ruberti JW, Curcio CA, Millican CL, Menco BPM, Huang J-D & Johnson M (2003): Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane. Invest Ophthalmol Vis Sci 44: 1753-1759.
20. Sparrow JR, Zhou J & Cai B (2003): DNA is a target of the, photodynamic effects elicited in A2E-laden RPE by blue-light illumination. Invest Ophthalmol Vis Sci 44: 2245-2251.
21. Sundelin SP & Nilsson SEG (2001): Lipofuscin formation in retinal pigment epithelial cells is reduced by antioxidants. Free Radic Biol Med 31: 217-225.
22. Taylor HR, Tikellis G, Robman LD, McCarty CA & McNeil JJ (2002): Vitamin E supplementation and macular degeneration: randomized, controlled trial. Br Med J 325: 11-14.